Dr. Jeremy Levin joins Ken Banta to share why he believes biotech's future demands a new level of leadership and stakeholder education — and why "mission without method" is a wasted effort.
News|Articles|February 7, 2025
Pfizer Appoints Jeffrey Legos as Chief Oncology Officer
Author(s)Don Tracy, Associate Editor
Legos will take over from Roger Dansey, who will begin transitioning to retirement.
Advertisement
Pfizer announced that it has appointed Jeffrey Legos, PhD, MBA, as its new chief oncology officer, succeeding Roger Dansey, MD, who will retire. According to the company, Legos will lead Pfizer’s oncology R&D division, overseeing all stages from preclinical to late-stage clinical development. Legos will report to Chris Boshoff, MD, PhD, chief scientific officer, president, Pfizer R&D.
Legos’s most recent role was as EVP, global head of oncology and hematology development for Novartis. According to Pfizer, Legos joins with over 20 years of experience in securing more than 40 global regulatory approvals for oncology drugs and companion diagnostics. Legos also contributed to the establishment of GSK’s oncology business unit as VP and global medicines development leader in oncology.
Legos holds a PhD in physiology from Temple University and an MBA in finance from Villanova University. He has also written over 40 manuscripts and abstracts for peer-reviewed journals. Further, he currently serves as a scientific advisor to the Melanoma Research Alliance, a strategic advisory board member for Gingko Bioworks.
Advertisement
Related to this article
New U.S. guidance carves out tariff exemptions for specialty pharmaceuticals, Pharming's Fabrice Chouraqui steps down as CEO amid a board rift, and a dealmaking roundup covers Hengrui Pharma's licensing agreement with Novo Nordisk and AstraZeneca's investment in Summit Therapeutics.
Pharming CEO Fabrice Chouraqui has stepped down amid strategic disagreements with the board, with chief commercial officer Leverne Marsh and chief financial officer Kenneth Lynard now serving as interim co-CEOs.
While the FDA weighs a narrow, regulated path for compounded peptides, its enforcement arm is already taking action.
EVERSANA's Jen Norton talks about how AI is reshaping market access strategy, a new analysis from MIT and Harvard Business School names clinical data harmonization as the real barrier to enterprise AI adoption in life sciences, and Novo Nordisk's CEO says he's open to a direct NYSE listing.
Novo Nordisk CEO Mike Doustdar says he's open to a direct NYSE listing that would replace the company's ADR structure.
Chairs of Europe's largest drugmakers urge the EU to boost health spending, speed up clinical trials, and strengthen IP protections before falling further behind the US and China.
Digital health's point-solution era is giving way to broader platforms, and the cost-savings claims those platforms make to employers often don't hold up to methodological scrutiny.
Advertisement
Advertisement
Trending on PharmExec
1
Novo Reports Real-World Data Showing Weight Loss After Switch to Oral Semaglutide Pill
2
Roundup: Hengrui Pharma and Novo Enter Exclusive License Agreement for HRS-1596, AstraZeneca Enters Collaboartion with Summit Therapeutics
3
New U.S. Guidance Lays Out Exemptions for 100% Tariffs: Report
4
As Peptide Rulemaking Stalls, FDA Enforcement Moves Forward
5